Management of acute anaphylaxis in clinical practice in the context of the guidelines
Authors:
Ch. P. Cmorej; M. Nesvadba; R. Babeľa; O. Slowik; R. Didič
Authors‘ workplace:
Vysoká škola zdravotníctva a sociálnej práce sv. Alžbety, Ústav zdravotníckych disciplín, Bratislava
Published in:
Epidemiol. Mikrobiol. Imunol. 66, 2017, č. 1, s. 30-38
Category:
Review Article
Overview
Anaphylaxis is a rapidly progressing, life-threatening allergic reaction that needs rapid diagnosis and treatment. Recent research has brought new information about the increasing incidence of anaphylaxis. Nevertheless, the prevalence and incidence of anaphylaxis are difficult to estimate due to the lack of consensus on the definition of anaphylaxis, differences between the population groups analysed, and use of different data collection methods. The most common triggers of anaphylaxis are food allergens, insect stings, and drugs. The serum tryptase level serves as a diagnostic indicator of anaphylaxis. In patients with normal serum tryptase levels, other inflammatory mediators need to be considered. Epinephrine is still the drug of choice for the therapy of severe anaphylaxis. The authors present new information about anaphylaxis from the recently published literature and/or guidelines
KEYWORDS:
anaphylaxis – epinephrine – guidelines – histamine – tryptase
Sources
1. Soar J, Deakin DCH, Nolan PJ, et al. European Resuscitation Council Guidelines for Resuscitation 2005 Section 7. Cardiac arrest in special circumstances. Resuscitation, 2005;67S1:135–170.
2. Soar J, Perkins GD, Abbas G, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation, 2010:1400–1433.
3. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol, 2004;113:832–836.
4. Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions – guidelines for healthcare providers. Resuscitation, 2008;77:157–169.
5. Soar J. Emergency treatment of anaphylaxis in adults: concise guidance. Clin Med, 2009;9:181–185.
6. Mimi LK, Osborne N, Allen K, Epidemiology of anaphylaxis. Curr Opin Allergy Clin Imunnol, 2009;9:351–356.
7. Lieberman P, Camargo Jr CA, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol, 2006;97:596–602.
8. Decker WW, Campbell RL, Manivannan V, et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol, 2008;122:1161–1165.
9. Clark S, Camargo CA Jr. Epidemiology of anaphylaxis. Immunol Allergy Clin North Am, 2007;27:145–163.
10. Peng MM, Jick H. A populationbased study of the incidence, cause, and severity of anaphylaxis in the United Kingdom. Arch Intern Med, 2004;164:317–319.
11. Mullins RJ. Anaphylaxis: risk factors for recurrence. Clin Exp Allergy, 2003;33:1033–1040.
12. Bohlke K, Davis RL, DeStefano F, et al. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. J Allergy Clin Immunol, 2004;113:536–542.
13. Simons FER, Ebisawa M, Sanchez-Borgez M, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J, 2015;8(1):32.
14. Wood RA, Camargo CA, Lieberman P, et al. Anaphylaxis in America: The prevalence and characteristics of anaphylaxis in the United States. J Allergy Clin Immunol, 2014;133:461–467.
15. Rudders SA, Arias SA, Camargo CA. Trends in hospitalizations for food-induced anaphylaxis in US children, 2000–2009. J Allergy Clin Immunol, 2014;134:960–962.
16. Nocerino R, Leone L, Cosenza L, et al. Increasing rate of hospitalizations for food-induced anaphylaxis in Italian children: an analysis of the Italian Ministry of Health database. J Allergy Clin Immunol, 2015;135:833–835.
17. Mullins RJ, Dear KBG, Tang MLK. Time trends in Australian hospital anaphylaxis admissions in 1998–1999 to 2011–2012. J Allergy Clin Immunol, 2015;136:367–375.
18. Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: An analysis of United Kingdom national anaphylaxis data, 1992–2012. J Allergy Clin Immunol, 2015;135:956–963.
19. Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999–2010: Temporal patterns and demographic associations. J Allergy Clin Immunol, 2014;134:1318–1328.
20. Simons FER, Sampson HA. Anaphylaxis: Unique aspects of clinical diagnosis and management in infants (birth to age 2 years). J Allergy Clin Immunol, 2015;135:1125–1131.
21. Vazquez-Ortiz M, Alvaro M, Piquer M, et al. Life-threatening anaphylaxis to egg and milk oral immunotherapy in asthmatic teenagers. Ann Allergy Asthma Immunol, 2014;113:482–484.
22. Lieberman P, Simons FER. Anaphylaxis and cardiovascular disease: therapeutic dilemmas. Clin Exp Allergy, 2015;45:1288–1295.
23. Stoevesandt J, Hain J, Stolze I. Angiotensin-converting enzyme inhibitors do not impair the safety of Hymenoptera venom immunotherapy build-up phase. Clin Exp Allergy, 2014;44:747–755.
24. Nassiri M, Babina M, Dölle S. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: Evidence for direct mast cell priming. J Allergy Clin Immunol, 2015;135:491–499.
25. Valent P. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy, 2014;44:914–920.
26. Gulen T, Hagglund H, Sander B. The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy, 2014;44:1179–1187.
27. Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol, 2014;133:520–528.
28. Broesby-Olsen S, Oropeza AR, Bindslev-Jensen C, et al. Recognizing mastocytosis in patients with anaphylaxis: Value of KIT D816V mutation analysis of peripheral blood. J Allergy Clin Immunol, 2015;135:262–264.
29. Fellinger C, Hemmer W, Wohrl S. Clinical characteristics and risk profile of patients with elevated baseline serum tryptase. Allergol Immunopathol (Madr), 2014;42:544–552.
30. Pravettoni V, Piantanida M, Primavesi L. Basal platelet-activating factor acetylhydrolase: Prognostic marker of severe Hymenoptera venom anaphylaxis. J Allergy Clin Immunol, 2014;133:1218–1220.
31. Fischer J, Hebsaker J, Caponetto P. Galactose-alpha-1,3-galactose sensitization is a prerequisite for pork-kidney allergy and cofactor-related mammalian meat anaphylaxis. J Allergy Clin Immunol, 2014;134:755–759.
32. Ansley L, Bonini M, Delgado L, et al. Pathophysiological mechanisms of exercise-induced anaphylaxis: an EAACI position statement. Allergy, 2015;70:1212–1221.
33. Brockow K, Kneissl D, Valentini L, et al. Using a gluten oral food challenge protocol to improve diagnosis of wheat-dependent exercise-induced anaphylaxis. J Allergy Clin Immunol, 2015;135:977–984.
34. Hox V, Desai A, Bandara G. Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. J Allergy Clin Immunol, 2015;135:729–736.
35. Umasunthar T, Leonardi-Bee J, Turner PJ, et al. Incidence of food anaphylaxis in people with food allergy: a systematic review and meta-analysis. Clin Exp Allergy, 2015;45:1621–1636.
36. Kamdar TA, Peterson S, Lau CH. Prevalence and characteristics of adult-onset food allergy. J Allergy Clin Immunol Pract, 2015;3:114–115.
37. Sicherer SH, Sampson HA. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol, 2014;133:291–307.
38. van der Valk JPM, Dubois AEJ, Gerth van Wijk R. Systematic review on cashew nut allergy. Allergy, 2014;69:692–698.
39. Commins SP, James HR, Stevens W, et al. Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose. J Allergy Clin Immunol, 2014;134:108–115.
40. Takahashi K, Taniguchi M, Fukutomi Y, et al. Oral mite anaphylaxis caused by mite-contaminated okonomiyaki/pancake-mix in Japan: 8 case reports and a review of 28 reported cases. Allergol Int, 2014;63:51–56.
41. Levy Y, Segal N, Nahum A, et al. Hypersensitivity to methylprednisolone sodium succinate in children with milk allergy. J Allergy Clin Immunol Pract, 2014;2:471–474.
42. Hamilton RG, Scheer DI, Gruchalla R. Casein-related anaphylaxis after use of an Everlast kickboxing glove. J Allergy Clin Immunol, 2015;135:269–271.
43. Sturm GJ, Kranzelbinder B, Schuster C, et al. Sensitization to Hymenoptera venoms is common, but systemic sting reactions are rare. J Allergy Clin Immunol, 2014;133:1635–1643.
44. Cifuentes L, Vosseler S, Blank S, et al. Identification of Hymenoptera venom-allergic patients with negative specific IgE to venom extract by using recombinant allergens. J Allergy Clin Immunol, 2014;133:909–910.
45. Banerji A, Rudders S, Clark S. Retrospective study of drug-induced anaphylaxis treated in the emergency department or hospital: patient characteristics, management, and 1-year follow-up. J Allergy Clin Immunol Pract, 2014;2:46–51.
46. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: A cohort study. J Allergy Clin Immunol, 2014;133:790–796.
47. Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: A retrospective population-based analysis. J Allergy Clin Immunol, 2015;135:745–752.
48. Gaeta F, Valluzzi RL, Alonzi C. Tolerability of aztreonam and carbapenems in patients with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol, 2015;135:972–976.
49. Uyttebroek AP, Sabato V, Bridts CH. Moxifloxacin hypersensitivity: uselessness of skin testing. J Allergy Clin Immunol Pract, 2015;3:443–445.
50. Mori F, Pecorari L, Pantano S, et al. Azithromycin anaphylaxis in children. Int J Immunopathol Pharmacol, 2014;27:121–126.
51. Faria E, Rodrigues-Cernadas J, Gaspar A, et al. Drug-induced anaphylaxis survey in Portuguese allergy departments. J Investig Allergol Clin Immunol, 2014;24:40–48.
52. Picaud J, Beaudouin E, Renaudin JM, et al. Anaphylaxis to diclofenac: nine cases reported to the Allergy Vigilance Network in France. Allergy, 2014;69:1420–1423.
53. Galvao VR, Castells MC. Hypersensitivity to biological agents – updated diagnosis, management, and treatment. J Allergy Clin Immunol Pract, 2015;3:175–185.
54. Craig TJ, Li H, Riedl M, et al. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. J Allergy Clin Immunol Pract, 2015;3:206–212.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2017 Issue 1
Most read in this issue
- Management of acute anaphylaxis in clinical practice in the context of the guidelines
- The prevalence of antibodies against Hepatitis E Virus in the Czech Republic: serological survey
- Foodborne botulism – a re-emerging public health challenge
- Infectious diseases and laboratory diagnosisin the Terezin Jewish Ghetto